C-FDAPOlatec
NLRP3 antagonists, inflammasome inhibition, oral therapeutics
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-FDAP
C-FDAPC-FDAPNLRP3 antagonists, inflammasome inhibition, oral therapeutics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Olatec NLRP3 antagonists, inflammasome inhibition, oral therapeutics
Olatec is a privately held biopharmaceutical company developing oral NLRP3 antagonist therapeutics for inflammatory diseases mediated by Interleukin-1. Its lead compound, dapansutrile, also known as OLT1177, selectively targets NLRP3 and inhibits production of IL-1β and IL-18. The company states that its platform includes approximately 40 pharmaceutical candidates and more than 180 patents and patent applications globally.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Olatec — Translational · Bottom quartile. Derived deterministically from 10 extracted project(s). Most-advanced status: phase 2. Band: translational. Modifiers: +5 depth (2 programs at…
Source: Deterministic